1. Home
  2. CMPR vs SUPN Comparison

CMPR vs SUPN Comparison

Compare CMPR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPR
  • SUPN
  • Stock Information
  • Founded
  • CMPR 1994
  • SUPN 2005
  • Country
  • CMPR Ireland
  • SUPN United States
  • Employees
  • CMPR N/A
  • SUPN N/A
  • Industry
  • CMPR Publishing
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMPR Consumer Discretionary
  • SUPN Health Care
  • Exchange
  • CMPR Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • CMPR 2.0B
  • SUPN 2.1B
  • IPO Year
  • CMPR N/A
  • SUPN 2012
  • Fundamental
  • Price
  • CMPR $49.75
  • SUPN $33.05
  • Analyst Decision
  • CMPR Strong Buy
  • SUPN Hold
  • Analyst Count
  • CMPR 2
  • SUPN 2
  • Target Price
  • CMPR $91.00
  • SUPN $36.00
  • AVG Volume (30 Days)
  • CMPR 220.9K
  • SUPN 464.2K
  • Earning Date
  • CMPR 01-29-2025
  • SUPN 02-25-2025
  • Dividend Yield
  • CMPR N/A
  • SUPN N/A
  • EPS Growth
  • CMPR 281.41
  • SUPN 130.79
  • EPS
  • CMPR 6.02
  • SUPN 1.07
  • Revenue
  • CMPR $3,357,327,000.00
  • SUPN $651,972,000.00
  • Revenue This Year
  • CMPR $5.20
  • SUPN $7.94
  • Revenue Next Year
  • CMPR $4.13
  • SUPN N/A
  • P/E Ratio
  • CMPR $8.31
  • SUPN $31.70
  • Revenue Growth
  • CMPR 4.60
  • SUPN 6.79
  • 52 Week Low
  • CMPR $47.83
  • SUPN $25.53
  • 52 Week High
  • CMPR $104.92
  • SUPN $40.28
  • Technical
  • Relative Strength Index (RSI)
  • CMPR 24.52
  • SUPN 32.98
  • Support Level
  • CMPR $47.83
  • SUPN $32.53
  • Resistance Level
  • CMPR $53.85
  • SUPN $39.99
  • Average True Range (ATR)
  • CMPR 2.47
  • SUPN 1.31
  • MACD
  • CMPR -0.70
  • SUPN -0.69
  • Stochastic Oscillator
  • CMPR 11.39
  • SUPN 6.71

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: